Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery UsingIn SilicoScreening Delay the Progression of an Illness in Prion-Infected Mice

The accumulation of abnormal prion protein (PrPSc) produced by the structure conversion of PrP (PrP (c)) in the brain induces prion disease. Although the conversion process of the protein is still not fully elucidated, it has been known that the intramolecular chemical bridging in the most fragile pocket of PrP, known as the "hot spot," stabilizes the structure of PrP (c) and inhibits the conversion process. Using our original structure-based drug discovery algorithm, we identified the low molecular weight compounds that predicted binding to the hot spot. NPR-130 and NPR-162 strongly bound to recombinant PrPin vitro, and fragment molecular orbital (FMO) analysis indicated that the high affinity of those candidates to the PrP is largely dependent on nonpolar interactions, such as van der Waals interactions. Those NPRs showed not only significant reduction of the PrP(Sc)levels but also remarkable decrease of the number of aggresomes in persistently prion-infected cells. Intriguingly, treatment with those candidate compounds significantly prolonged the survival period of prion-infected mice and suppressed prion disease-specific pathological damage, such as vacuole degeneration, PrP(Sc)accumulation, microgliosis, and astrogliosis in the brain, suggesting their possible clinical use. Our results indicate thatin silicodrug discovery using NUDE/DEGIMA may be widely useful to identify candidate compounds that effectively stabilize the protein.